详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：

机构： [1]Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China [2]Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou, Peoples R China [3]Fudan Univ, Dept Colorectal Surg, Shanghai Canc Ctr, Shanghai, Peoples R China [4]Hubei Canc Hosp, Dept Abdominal Oncol, Wuhan, Peoples R China [5]Jilin Canc Hosp, Changchun, Peoples R China [6]Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou, Peoples R China [7]Peoples Hosp Guangxi Zhuang Autonomous Reg, Dept Med Oncol, Nanning, Peoples R China [8]Anhui Med Univ, Dept Oncol, Hosp 2, Hefei, Peoples R China [9]Liaoning Canc Hosp & Inst, Shenyang, Peoples R China [10]First Peoples Hosp Foshan, Dept Gastrointestinal Oncol, Foshan, Peoples R China [11]Capital Med Univ, Beijing Friendship Hosp, Dept Oncol, Beijing, Peoples R China [12]Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Dept Abdominal Oncol,Affiliate Canc Hosp, Chengdu, Peoples R China [13]Shandong First Med Univ, Jinan Cent Hosp, Dept Oncol, Cent Hosp, Jinan, Peoples R China [14]Guangxi Med Univ, Dept Gastrointestinal Surg, Canc Hosp, Nanning, Peoples R China [15]Zhengzhou Univ, Henan Canc Hosp, Dept Med Oncol, Affiliated Canc Hosp, Zhengzhou, Peoples R China [16]Linyi Canc Hosp, Dept Med Oncol, Linyi, Peoples R China [17]Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Med Oncol, Peoples Hosp, Hangzhou, Peoples R China [18]Shanghai Henlius Biotech Inc, Shanghai, Peoples R China

出处：

DOI：

ISSN：

关键词： 283-237-255 261-492-2769 613-225-313 613-135-244-3829 613-225-2575-3984 261-374 130-540-543-4790 7 4 3 2 1791 4287 182 6 38092-29187 38092-20072 1

基金：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 ONCOLOGY

影响因子： 42.1 最新[2023版] 37.4 最新五年平均 42.1 出版当年[2023版] 0 出版当年五年平均 42.1 出版前一年[2023版]

第一作者：

第一作者机构： [1]Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study [2]KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation [3]Phase II clinical study evaluating the efficacy and safety of disitamab vedotin combined with sintilimab and S-1 in the conversion treatment of HER2-overexpression unresectable gastric cancer [4]Unveiling prognosis and traits of dMMR/MSI-H gastric and colorectal cancer after curative surgery: A large-scale, multi-center, retrospective study in China [5]Discovery of 4-((3 ' R,4 ' S,5 ' R)-6 ''-Chloro-4 '-(3-chloro-2-fluorophenyl)-1 '-ethyl-2 ''-oxodispiro[cyclohexane-1,2 '-pyrrolidine-3 ',3 ''-indoline]-5 '-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development [6]4-(4′-取代苯基)氨基-6,7-二甲氧基喹唑啉衍生物的合成与抗肿瘤活性研究 [7]Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer. [8]Synthesis, biological evaluation and molecular docking study of N-(2-methoxyphenyl)-6-((4-nitrophenyl)sulfonyl)benzamide derivatives as potent HIV-1 Vif antagonists. [9]Ultrasound-guided microwave ablation for giant breast leiomyoma: A case report [10]Soluble epoxide hydrolase inhibitor 1-trifluoromethoxyphenyl-3- (1-propionylpiperidin-4-yl) urea attenuates bleomycin-induced pulmonary fibrosis in mice.